Molecular Imaging of NET Using [C-11]MRB-PET in MS
Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis
What it found
No result yet.
What was tested
Treatment tested
- [C-11]Methylreboxetine
What it measured
Main measures
[C-11]Methylreboxetine area under the curve ratios
Baseline
Who could take part
MS (type not specified) · 18 to 60
Show the full criteria
Inclusion criteria
1. Individuals meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 7.5 2. Male and female subjects age 18 to 70 years 3. Subjects willing to undergo PET and MRI imaging 4. Subjects willing and able to give informed consent
Exclusion criteria
1. Individuals with a comorbid severe psychiatric condition such as schizophrenia, bipolar disorder, or post-traumatic stress disorder. 2. Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse. 3. Individuals taking tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, or norepinephrine-dopamine reuptake inhibitors. 4. Concurrent medical conditions that contraindicate study procedures. 5. Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment. 6. Claustrophobia 7. Non-MRI compatible implanted devices 8. Corticosteroid treatment in the past four weeks
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
This study aims to use [C-11]MRB PET (positron emission tomography) imaging to look at brain injury in patients with Multiple Sclerosis (MS) and healthy individuals. The overarching hypothesis is that there is decreased radioligand binding to the norepinephrine transporter in multiple sclerosis, reflecting injury to the noradrenergic system and that it plays a role in disease pathogenesis, its clinical manifestations and severity. This strategy is targeted to address an unmet need because currently available MRI techniques lack sensitivity and specificity for assessing such changes in the brains of people with MS. The specific aims of the study are: 1. To determine norepinephrine transporter binding in the brains of MS patients using [C-11]MRB PET and compare it with age, and sex matched healthy controls. 2. To determine correlation of norepinephrine transporter binding with clinical severity and MRI parameters in MS. 3. To determine correlation of norepinephrine transporter binding with fatigue and cognitive impairment in MS patients.
Papers
Loading reviews and guidelines…
Related trials
- [18F]F-DED PET Imaging of Reactive Astrocytes in Multiple Sclerosis
Not a drug-phase study · Not yet recruiting
Still running
- This Study Involves a Positron Emission Tomography (PET) Scan Using a
Recruiting
Still running
- Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Phase 1 · Recruiting
Still running
- Smoldering Inflammation in MS
Recruiting
Still running
- A Study of Imaging in Demyelinating Diseases
Phase 2 · Enrolling by invitation
Still running
- Investigating the Utility of Demyelination Tracer [18F]3F4AP in Contro
Phase 1 · Recruiting
Still running
History
Started
Oct 2017
Main results due
Dec 2026
Finished
Dec 2026